[
    "{\"step_by_step_thinking\": \"Figitumumab is a monoclonal antibody that targets the insulin-like growth factor-1 receptor and was investigated for the treatment of various types of cancer, including non-small cell lung cancer (NSCLC). However, according to Document [1], the development of the drug was ceased by Pfizer in January 2011. Document [3] and Document [15] also mention that the clinical development of figitumumab has been discontinued due to lack of efficacy and increased incidence of serious adverse events. Therefore, it can be concluded that figitumumab is not effective for non-small cell lung cancer.\", \"answer_choice\": \"B\"}"
]